Topics

STAT Plus: Will an FDA panel recommend a drug for preventing premature births remain available?

15:57 EDT 28 Oct 2019 | STAT

A drug to prevent premature births will be reviewed by an FDA advisory panel on Tuesday amid intensifying debate over whether Makena should remain on the market.

Original Article: STAT Plus: Will an FDA panel recommend a drug for preventing premature births remain available?

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Will an FDA panel recommend a drug for preventing premature births remain available?"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...